- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03675529
The Effect of Exercise on Tumor Hypoxia in Men With Localized Prostate Cancer Undergoing Radical Prostatectomy. (SHOR-TEST)
The Effect of Exercise on Tumor Hypoxia in Men With Localized Prostate Cancer Undergoing Radical Prostatectomy - a Randomized Controlled Pilot Study
Background and purpose: The purpose of this study is to investigate the effect of one acute exercise bout on tumor hypoxia in patients with localized prostate cancer undergoing radical prostatectomy.
The primary hypothesis is that exercise reduces tumor hypoxia and that the reduction is greater in patients performing one acute high intensity exercise bout compared to no training controls.
The investigators have not been able to identify any prior or current randomized trials investigating exercise and tumor hypoxia, and believe that such research is warranted and would be of great importance. Moreover there is a need for studies including biological measurements to allow a full assessment of the effect of exercise on diverse biomarkers and mechanistic pathways, which may influence cancer survival.
Subjects: Patients with histologically verified prostate adenocarcinoma scheduled for radical prostatectomy at Urologic Department, Rigshospitalet, Copenhagen, Denmark.
Methods: In this randomized controlled pilot study 30 patients with localized prostate cancer undergoing radical prostatectomy will be included and randomized 2:1 to either one single acute High Intensity Interval Training bout or usual care and no training the day prior to radical prostatectomy.
All patients will undergo assessment at inclusion (baseline) and the day prior to surgery.
Assessment includes: anthropometrics; blood pressure; resting hearth rate; hip and waist circumference, ECG, quality of life by self-report questionnaires; fasting blood sample measuring PSA (prostate specific antigen), cholesterol, triglycerides, insulin, c-peptide, HbA1c, glucose and inflammatory markers.
All patients will receive one dose of pimonidazole hydrochloride (500 mg per m2 body surface) in order to quantify tumor hypoxia by pathological analyses after removal of the prostate.
Biological tissue from tumor (primary prostate biopsies) will also be retrieved from the respective local pathological departments and from the perioperative prostate specimen and sent to protocol analyses.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to investigate the effect of one acute exercise bout on tumor hypoxia in patients with localized prostate cancer randomized to one single acute I) High Intensity Interval Training bout compared to (II) usual care and no training prior to radical prostatectomy.
In addition to this the aim is to investigate the effect of one exercise bout on tumor vessel morphology and to investigate the effect of one acute exercise bout on intratumoral immune cell infiltration and to investigate the modulation of tumor-metabolism, -biology and signaling in patients randomized to either one acute High Intensity Interval Training bout compared to usual care and no training, the day prior to surgery.
Moreover this study will explore the acute response in immune cells, hormones and cytokines in blood samples taken before, during and after a single exercise session, and will collect physiological (metabolic profile and metabolic inflammatory markers) and psycho-social (e.g. fatigue, emotional well-being, anxiety) information regarding patients randomized to either one acute High Intensity Interval Training bout compared to usual care and no training, the day prior to surgery.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark, DK-2100
- Center for Physical Activity Research, Copenhagen University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men with histologically verified localized prostate adenocarcinoma undergoing curative intended radical prostatectomy.
Exclusion Criteria:
- Age: <18 years
- Any other known malignancy requiring active treatment
- Performance status > 1
- Allergy to pimonidazole
- Ongoing treatment with beta blockers
- Physical disabilities precluding physical testing and/or exercise
- Inability to read and understand Danish
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: High Intensity Interval Training bout
Patients randomized to this group will perform a wattmax test immediately followed by 4 intervals of high and low intensity based on percentage of wattmax.
Immediately after the exercise bout is finished patients will receive one dose of pimonidazole hydrochloride (500 mg per m2 body surface) in order to quantify tumor hypoxia by pathological analyses after removal of the prostate by radical prostatectomy the following day.
|
Patients randomized to the HIIT bout will perform one single supervised High Intensity Interval Training bout consisting firstly of a wattmax test on a stationary bike, in order to set the training intensity.
This is followed by 10 minutes at low intensity at approximately 30% of wattmax.
Subsequently patients will perform 16 min with 4 cycles with High and Low intensity.
HI intervals consisting of 1 min with 100% of wattmax followed by 3 min recovery with the intensity load of 30% of wattmax.
|
No Intervention: Controls (usual care)
Patients randomized to the control group will not be doing any exercise, but will after approximately 35 min from baseline blood sampling receive one dose of pimonidazole hydrochloride (500 mg per m2 bodysurface) in order to quantify tumor hypoxia by pathological analyses after removal of the prostate by radical prostatectomy the following day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor hypoxia
Time Frame: At prostatectomy
|
Quantification of tumor hypoxia will be assessed using pimonidazole staining
|
At prostatectomy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intratumoral immune cell infiltration
Time Frame: Primary prostate biopsies and until radical prostatectomy
|
Intratumoral immune cell infiltration will be quantified using histological analyses
|
Primary prostate biopsies and until radical prostatectomy
|
Tumor vessel morphology
Time Frame: Primary prostate biopsies and until radical prostatectomy
|
Tumor vessel morphology will be evaluated using histological analyses
|
Primary prostate biopsies and until radical prostatectomy
|
Tumor metabolism-, biology and signaling
Time Frame: Primary prostate biopsies and until radical prostatectomy
|
Tumor samples will undergo proteomic analyses in order to uncover potential upregulated biomarkers
|
Primary prostate biopsies and until radical prostatectomy
|
Changes in immune cells during an acute exercise bout
Time Frame: From start of exercise bout and until 60 minutes post exercise
|
Changes in immune cells during an acute exercise bout will be measured in blood samples using flowcytometry
|
From start of exercise bout and until 60 minutes post exercise
|
Changes in epinephrine concentration
Time Frame: From start of exercise bout and until 60 minutes post exercise
|
Concentration of epinephrine will be measured in blood samples by radioimmunoassay analyses.
|
From start of exercise bout and until 60 minutes post exercise
|
Changes in nor-epinephrine concentration
Time Frame: From start of exercise bout and until 60 minutes post exercise
|
Concentration of nor-epinephrine will be measured in blood samples by radioimmunoassay analyses.
|
From start of exercise bout and until 60 minutes post exercise
|
Changes in various interleukines
Time Frame: From start of exercise bout and until 60 minutes post exercise
|
Concentration of various interleukines will be measured in blood samples by measured in blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses.
|
From start of exercise bout and until 60 minutes post exercise
|
Changes in Tumor Necrosis Factor alpha (TNFa) concentration
Time Frame: From start of exercise bout and until 60 minutes post exercise
|
Concentrations of TNFa will be measured in blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses.
|
From start of exercise bout and until 60 minutes post exercise
|
Changes in Interferon Gamma (IFNγ) concentration
Time Frame: From start of exercise bout and until 60 minutes post exercise
|
Concentrations of IFNγ will be measured in blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses.
|
From start of exercise bout and until 60 minutes post exercise
|
Concentration of C-reactive Protein (CRP)
Time Frame: Blood sampling on the day of radical prostatectomy
|
Concentration of CRP will be measured in fasting blood sample by standard laboratory methods.
|
Blood sampling on the day of radical prostatectomy
|
Total plasma cholesterol concentration
Time Frame: Blood sampling on the day of radical prostatectomy
|
Concentrations of total cholesterol will be measured in fasting blood samples by standard laboratory methods.
|
Blood sampling on the day of radical prostatectomy
|
Plasma LDL-Cholesterol concentration
Time Frame: Blood sampling on the day of radical prostatectomy
|
Concentrations of LDL- cholesterol will be measured in fasting blood samples by standard laboratory methods.
|
Blood sampling on the day of radical prostatectomy
|
Plasma HDL-Cholesterol concentration
Time Frame: Blood sampling on the day of radical prostatectomy
|
Concentrations of HDL- cholesterol will be measured in fasting blood samples by standard laboratory methods.
|
Blood sampling on the day of radical prostatectomy
|
Plasma triglyceride concentrations
Time Frame: Blood sampling on the day of radical prostatectomy
|
Concentrations of triglycerides will be measured in fasting blood samples by standard laboratory methods.
|
Blood sampling on the day of radical prostatectomy
|
HbA1C concentration
Time Frame: Blood sampling on the day of radical prostatectomy
|
Concentrations of HbA1C will be measured in fasting blood samples by standard laboratory methods.
|
Blood sampling on the day of radical prostatectomy
|
Plasma Insulin concentration
Time Frame: Blood sampling on the day of radical prostatectomy
|
Concentrations of insulin will be measured in fasting blood samples by standard laboratory methods.
|
Blood sampling on the day of radical prostatectomy
|
Plasma Glucose concentration
Time Frame: Blood sampling on the day of radical prostatectomy
|
Concentrations of glucose will be measured in fasting blood samples by standard laboratory methods.
|
Blood sampling on the day of radical prostatectomy
|
Wattmax-test
Time Frame: At baseline assessment
|
The participants in the HIIT group will undergo a maximal graded exercise test on a bicycle ergometer for evaluation of cardiovascular function and determination of the maximum watt (wattmax).
The test starts with a 3 min warm up at 70 watt (the watts may have to be adjusted to the individual fitness level).
Warm up is immediately followed by a 20 watt increase every 1 min until exhaustion.
The maximum watt will be calculated.
|
At baseline assessment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sissal S Djurhuus, MD, PhD student
Publications and helpful links
General Publications
- Djurhuus SS, Schauer T, Simonsen C, Toft BG, Jensen ARD, Erler JT, Roder MA, Hojman P, Brasso K, Christensen JF. Effects of acute exercise training on tumor outcomes in men with localized prostate cancer: A randomized controlled trial. Physiol Rep. 2022 Oct;10(19):e15408. doi: 10.14814/phy2.15408.
- Schauer T, Djurhuus SS, Simonsen C, Brasso K, Christensen JF. The effects of acute exercise and inflammation on immune function in early-stage prostate cancer. Brain Behav Immun Health. 2022 Sep 7;25:100508. doi: 10.1016/j.bbih.2022.100508. eCollection 2022 Nov.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-18020711
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on High Intensity Interval Training bout
-
University of VirginiaCompletedAging WellUnited States
-
University Hospital TuebingenRecruiting
-
University of Kansas Medical CenterCompletedStroke | High Intensity Interval ExerciseUnited States
-
University of MichiganCompletedGlucose IntoleranceUnited States
-
Universidad SurcolombianaMaciste Macias; Gilberto AstaizaRecruiting
-
Kuopio Research Institute of Exercise MedicineKuopio University Hospital; University of Basel; University of Eastern Finland; Social Insurance Institution, FinlandTerminatedUnstable Angina Pectoris | Acute Myocardial Infarction | Recurrent Myocardial InfarctionFinland
-
Cairo UniversityKasr El Aini HospitalCompletedDiabetes Mellitus, Type 2Egypt
-
Universidad Santo TomasCompletedMetabolic DiseasesColombia
-
Norwegian University of Science and TechnologySt. Olavs Hospital; Liverpool John Moores University; Australian Catholic UniversityCompletedPolycystic Ovary SyndromeAustralia, Norway
-
Norwegian University of Science and TechnologySt. Olavs Hospital; Liverpool John Moores University; Australian Catholic UniversityCompletedPolycystic Ovary SyndromeAustralia, Norway